Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials

PURPOSE: In recent years, a number of clinical trials have shown that programmed death 1 (PD-1) inhibitors offer significant survival benefits in patients with esophageal squamous cell carcinoma (ESCC). We conducted a meta-analysis to explore the antitumour efficacy of PD-1 inhibitor-based therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yao, Wang, Wenkang, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185849/
https://www.ncbi.nlm.nih.gov/pubmed/37205107
http://dx.doi.org/10.3389/fimmu.2023.1171671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185849/
https://www.ncbi.nlm.nih.gov/pubmed/37205107
http://dx.doi.org/10.3389/fimmu.2023.1171671

Ejemplares similares